These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24658085)

  • 1. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
    Kawabata S; Chiang CT; Tsurutani J; Shiga H; Arwood ML; Komiya T; Gills JJ; Memmott RM; Dennis PA
    Oncotarget; 2014 Feb; 5(4):1062-70. PubMed ID: 24658085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
    Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
    Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
    Markova B; Hähnel PS; Kasper S; Herbertz S; Schuler M; Breitenbuecher F
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):545-54. PubMed ID: 22203472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
    Takezawa K; Okamoto I; Okamoto W; Takeda M; Sakai K; Tsukioka S; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
    Br J Cancer; 2011 May; 104(10):1594-601. PubMed ID: 21487406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.
    Liu Y; Yin TJ; Zhou R; Zhou S; Fan L; Zhang RG
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1125-32. PubMed ID: 24067998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
    Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
    J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
    Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase inhibitors for non-small cell lung cancer.
    Galvani E; Peters GJ; Giovannetti E
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1343-56. PubMed ID: 21905922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.
    Sun JM; Ahn JS; Jung SH; Sun J; Ha SY; Han J; Park K; Ahn MJ
    J Clin Oncol; 2015 Aug; 33(22):2450-6. PubMed ID: 26124486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.
    Frings V; van der Veldt AA; Boellaard R; Herder GJ; Giovannetti E; Honeywell R; Peters GJ; Thunnissen E; Hoekstra OS; Smit EF
    PLoS One; 2013; 8(5):e63705. PubMed ID: 23717468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
    Giovannetti E; Honeywell R; Hanauske AR; Tekle C; Kuenen B; Sigmond J; Giaccone G; Peters GJ
    Curr Drug Targets; 2010 Jan; 11(1):12-28. PubMed ID: 19839931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis.
    Wang L; Wang R; Pan Y; Sun Y; Zhang J; Chen H
    BMC Cancer; 2014 Mar; 14():205. PubMed ID: 24641970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
    Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
    Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.
    Wang X; Wang Y; Wang Y; Cheng J; Wang Y; Ha M
    J Biomed Sci; 2013 Jan; 20(1):5. PubMed ID: 23350714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Sun JM; Han J; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
    Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
    Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed.
    Patki M; Gadgeel S; Huang Y; McFall T; Shields AF; Matherly LH; Bepler G; Ratnam M
    J Thorac Oncol; 2014 Apr; 9(4):519-26. PubMed ID: 24736075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.